Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019Joong Sik Eom, Shinhye Cheon, Han Na Kim et al.|Open Forum Infectious Diseases|2022Cited by 42